Prognostic Significance of C-reactive Protein in Urological Cancers: a Systematic Review and Meta-analysis

Dai, Jin; Tang, Kun; Wei, Xiao; Gan, Yuhong; Jin, Zhaohui; Li, Wei; Zhang, Yaqun; Xu, Hua; Chen, Zhiqiang; Ye, Zhangqun

doi:10.7314/apjcp.2014.15.8.3369

Cited by 39 publications

(28 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of various serum biomarkers in determining the prognosis for different types of cancer has been widely investigated [15], [16], [17], [18]. Most of these tested biomarkers are related to systemic inflammatory process of a sort.…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma

Aggerholm‐Pedersen

Maretty-Kongstad

Keller

et al. 2016

Translational Oncology

View full text Add to dashboard Cite

OBJECTIVE: Certain biomarkers such as the C-reactive protein, serum albumin, and the neutrophils to lymphocyte ratio are of prognostic significance regarding survival in different types of cancers. Data from sarcoma patients are sparse and mainly derived from soft tissue sarcoma and/or metastatic cases. Adjusting for confounders such as comorbidity and age is an essential safeguard against erroneous conclusions regarding the possible prognostic value of these biomarkers. The aim of this study was to assess the prognostic value of a battery of pretreatment biomarkers in the serum of patients with localized bone sarcomas and to adjust for potential confounders. MATERIAL AND METHODS: All patients diagnosed with localized intermediate and high-grade bone sarcoma during 1994 to 2008 were extracted from the Aarhus Sarcoma Registry. The serum levels of albumin, C-reactive protein, hemoglobin, neutrophils, lymphocytes, and sodium were collected from the patient records. The prognostic values of overall and disease-specific mortality were tested for each individual biomarker as well as for the Glasgow prognostic score (GPS) and for a new composite score incorporating five biomarkers (Aarhus composite biomarker score: ACBS). Adjustments were made for comorbidity as well as other possible prognostic factors, such as size, histological type, margin, chemotherapy, and soft tissue extension, using the Cox proportional hazard model. RESULTS: A total of 172 patients with high- or intermediate-grade localized bone sarcoma were included. Of these patients, 63 were diagnosed with chondrosarcoma and 109 patients with Ewing/osteosarcoma. The median age was 55 years for chondrosarcoma and 19 years for Ewing/osteosarcoma patients. The overall 5-year mortality was 31% [95% confidence interval (CI): 21-44] and 41% (95% CI: 33-51), whereas the 5-year disease-specific mortality was 21% (95% CI: 12-34) and 39% (95% CI: 31-49) for chondrosarcoma and Ewing/osteosarcoma, respectively. Comorbidities were present in 12% of the Ewing/osteosarcoma patients and in 24% of the chondrosarcoma patients. After adjustment for comorbidity and other confounders, it was found that elevated levels of CRP, low hemoglobin, low sodium, high GPS, and high ACBS were associated with increased overall mortality. Furthermore, elevated levels of CRP, low hemoglobin, high GPS, and high ACBS were associated with increased disease-specific mortality. CONCLUSION: Elevated levels of CRP, low hemoglobin, high GPS, and high ACBS were all independent prognostic factors for both overall and disease-specific mortality. ACBS is a new three-level score of five biomarkers, but its value has to be confirmed in an independent data set.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma

Aggerholm‐Pedersen

Maretty-Kongstad

Keller

et al. 2016

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…(Gabay et al, 1999;Mantovani et al, 2008;Yildirim et al, 2013). In several studies, high inflammatory parameters (CRP, alpha and gamma globulins, neutrophil lymphocyte ratio (NLR), complement C3-C4) were found and associated with reduced overall survival in patients with different cancers including lung cancers (Shimada et al, 2003;Canna et al, 2005;Kaya et al, 2013;Zheng et al, 2013;Dai et al, 2014;Soliman et al, 2014). Increasing synthesis of acute phase proteins and interleukins and tumor necrosis-related hypoxia may be the mechanisms underlying this increased inflammation (McMillan et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients

Duran¹,

İnanç²,

Karaca³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (15), [6449][6450][6451][6452][6453] Introduction Non-small cell lung cancer (NSCLC), which includes a broad range of lung tumors encompassing squamous cell carcinomas and adenocarcinomas as the major subtypes, is the most common cause of cancer related death (Jemal et al., 2010). In patients with lung adenocarcinoma, only a few parameters are described as a prognostic factors such as stage of disease, tumor metabolism, high GLUT1 expression and performance status (de Geus-Qei et al., 2007;Andersen et al., 2011).Serum total proteins contain albumin, globulins and other inflammatory proteins such as C-reactive protein (CRP), interleukins and tumor necrosis factors (McPherson et al., 2006). Albumin and globulins play a pivotal role in the inflammatory process . Serum albumin is also an objective parameter that reflects the degree of long-term nutrition status (Laky et al., 2007

show abstract

“…Recently more and more researches have focused on the prognostic value of CRP in cancers. It is shown that elevated CRP level predicts a worse outcome in cancer patients, especially in gastric cancer and urological cancer (Guo et al, 2013;Yu et al, 2013;Dai et al, 2014). However, the relationship between elevated CRP level and the prognosis of esophageal cancer is unclear, and there is a lack of large scale, multicentric clinical trial to solve this problem.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Zheng

Cao²,

Cui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The classical inflammatory biomarker, C-reactive protein (CRP), has been identified to be related to progression of esophageal cancer. Some research showed that elevated pretreatment serum CRP indicated a poor prognosis, but results have been inconsistent. Materials and Methods: We searched the Medline, Embase and the Cochrane Central Search Library for suitable studies and a meta-analysis of eleven (1,886 patients) was conducted to examine the relationship between elevated serum CRP level and overall survival (OS) in esophageal cancer cases. Moreover, correlation analyses were conducted to assess links between pretreatment serum CRP level and tumor node metastasis (TNM) stage as well as T, N, M grade, respectively. Results: The pooled analysis showed that elevated pretreatment serum CRP level was significantly associated with poorer overall survival (HR 2.09, 95%CI 1.52-2.87, p<0.01). Subgroup analyses were conducted by "country", "cut-off value", "treatment" and "number of patients", and no single factor could alter the result. Elevated pretreatment serum CRP was significantly correlated with more advanced TNM stage and T, N, M grade respectively. Conclusions: Elevated pretreatment serum CRP levels are associated with poorer prognosis in esophageal cancer patients, and could serve as a useful biomarker for outcome prediction.

show abstract

Prognostic Significance of C-reactive Protein in Urological Cancers: a Systematic Review and Meta-analysis

Cited by 39 publications

References 59 publications

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma

Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients

Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis

Contact Info

Product

Resources

About